	US 11,718,672 B2
	CD137- and DLL3-targeting multispecific antigen-binding molecules
Sotaro Naoi, Shizuoka (JP); Shu Feng, Singapore (SG); Tomoyuki Igawa, Singapore (SG); and Shu Wen Samantha Ho, Singapore (SG)
Assigned to Chugai Seiyaki Kabushiki Kaisha, Tokyo (JP)
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed on Feb. 14, 2022, as Appl. No. 17/670,917.
Application 17/670,917 is a continuation of application No. 17/216,981, filed on Mar. 30, 2021, granted, now 11,274,151.
Claims priority of application No. 2020-062326 (JP), filed on Mar. 31, 2020.
Prior Publication US 2022/0251201 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2809 (2013.01) [C07K 16/28 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)]

28 Claims

1. A pharmaceutical composition comprising

(1) a multispecific antigen-binding molecule that comprises:

(a) a first antigen-binding moiety and a second antigen-binding moiety, at least one of which binds to human CD137 and comprises an antibody variable region comprising a heavy chain CDR 1 comprising SEQ ID NO: 20, a heavy chain CDR 2 comprising SEQ ID NO: 34, a heavy chain CDR 3 comprising SEQ ID NO: 48, a light chain CDR 1 comprising SEQ ID NO: 63, a light chain CDR 2 comprising SEQ ID NO: 68, and a light chain CDR 3 comprising SEQ ID NO: 73; and

(b) a third antigen-binding moiety that binds to human Delta-like 3 (DLL3) and comprises an antibody variable region comprising a heavy chain CDR1 comprising SEQ ID NO: 233, a heavy chain CDR 2 comprising SEQ ID NO: 234, a heavy chain CDR 3 comprising SEQ ID NO: 235, a light chain CDR 1 comprising SEQ ID NO: 237, a light chain CDR 2 comprising SEQ ID NO: 238, and a light chain CDR 3 comprising SEQ ID NO: 239; and

(2) a pharmaceutically acceptable carrier.